维普中文期刊产品整合服务
3篇 您的检索式:作者名="Handan Canan"
    题名 作者 年代 出处 被引量
1Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion显示文摘AIM: To evaluate central macular thickness(CMT) and mean choroidal thickness(MCT) in eyes with branch retinal vein occlusion(BRVO), before and after ranibizumab treatment using spectral domain-optical coherence tomography(SD-OCT).·METHODS: Forty-two patients with unilateral BRVO and macular edema were included in this study. There were 25 men and 17 women. Using SD-OCT, choroidal thickness was measured at 500 μm intervals up to 1500μm temporal and nasal to the fovea. MCT was calculated based on the average of the 7 locations. All the eyes with BRVO were treated with intravitreal ranibizumab(0.5 mg/0.05 m L). Comparisons between the BRVO and fellow eyes were analyzed using Mann-Whitney U test. Preinjection and post-injection measurements were analyzed using Wilcoxon test and repeated measure analysis.· RESULTS: At baseline, there was a significant difference between the BRVO and fellow eyes in MCT[BRVO eyes 245(165-330) μm, fellow eyes 229(157-327) μm]and CMT [BRVO eyes 463(266-899) μm, fellow eyes 235(148-378) μm(P =0.041, 0.0001, respectively)]. Following treatment, CMT [295(141-558) μm] and MCT [229(157-329) μm] decreased significantly compared to the baseline measurements(P =0.001, 0.006, respectively).Also BCVA(log MAR) improved significantly(P=0.0001) in the BRVO eyes following treatment. After treatment CMT[BRVO eyes 295(141-558) μm, fellow eyes 234(157-351) μm]and MCT [BRVO eyes 229(157-329) μm, fellow eyes 233(162-286) μm] values did not reveal any significant difference in BRVO eyes and fellow eyes(P=0.051, 0.824,respectively).· CONCLUSION: In eyes with BRVO, CMT and MCT values are greater than the fellow eyes, and decrease significantly following ranibizumab injection.Muge Coban-Karatas Rana Altan-Yaycioglu Burak Ulas Selcuk Sizmaz Handan Canan Cagla Sariturk 2016International Journal of Ophthalmology(English edition)2016,9,5:6
2Effect of diluted povidone iodine in adenoviral keratoconjunctivitis on the rate of subepithelial corneal infiltrates显示文摘AIM: To evaluate the clinical characteristics of adenoviral keratoconjunctivitis, the management modalities, as well as the incidence of subepithelial corneal infiltrates(SEI).METHODS: Patients with characteristic clinical symptoms and signs, who presented to our clinic within the first week of symptoms and received the diagnosis of adenoviral keratoconjunctivitis between January 2013 and April 2016, were included in the study. A total of 211 patients were included in the study. Patients were evaluated for the incidence of clinical signs, late complications, management preferences, and the effect of diluted povidone-iodine(d-PVP-I) 2%. RESULTS: Patients’ mean age was 33.03±14.76 y. We observed an increase in the number of cases according to the years. At presentation and/or early follow-up, the clinical signs were conjunctival hyperemia(100%), conjunctival follicules(79.1%), edema of the eyelids(39.3%), chemosis(16.1%), pseudomembrane formation(16.6%), and corneal epitheliopathy(29.9%). During late follow-up 13.3% patients developed conjunctival subepithelial fibrosis, and 39.8% developed SEI. A significant decrease in the incidence of SEI development was observed in patients who used d-PVP-I 2%(P=0.032;33.3% vs 45.9%, respectively in patients who received d-PVP-I 2% and who did not).CONCLUSION: Adenoviral keratoconjunctivitis has a tremendous effect on patient’s comfort and abilities in short-term. Additionally, almost half of the patients develop visual problems related to SEI. According to our clinical experience, using d-PVP-I 2% in the first days of adenoviral keratoconjunctivitis might be helpful in reducing the risk of SEI as a complication.Rana Altan-Yaycioglu Nedime Sahinoglu-Keskek Handan Canan Muge Coban-Karatas Burak Ulas 2019International Journal of Ophthalmology(English edition)2019,12,9:2
3Nasolacrimal Duct Obstruction: Clinicopathologic Analysis of 205 Cases显示文摘Rana Altan-Yaycioglu Handan Canan Selcuk Sizmaz Nebil Bal Aysel Pelit Yonca A. Akova 2010Orbit2010,,5:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费